India and South Africa approached World Trade Organisation to negotiate the temporary waiver of Intellectual Property (IP) rights on Covid-19 vaccines to remove the artificial barrier of patents and boost vaccine production. This commentary advocates for the waiver of IP rights on Covid-19 vaccines. First, the article makes a case for the debate on the validity of the Covid-19 vaccine to qualify for a patent. Market failure and underinvestment in research and development arguments do not hold for granting a patent to Covid vaccines. Next, the article briefly reviews the evidence on the association between vaccination and virus mutations. Evidence suggests that waiving patents is vital to increase vaccination worldwide and curb mutation and reduce the risk of more infectious new variants. Finally, the article argues that the rationale for a patent is economical, based on incentivising innovation and therefore, the losses suffered by various sectors of the economy due to new variants induced fatalities and lockdowns need to be considered for a case for its waiver.

印度和南非与世界贸易组织接洽，就暂时放弃 Covid-19 疫苗的知识产权 (IP) 权利进行谈判，以消除专利的人为障碍并促进疫苗生产。该评论主张放弃对 Covid-19 疫苗的知识产权。首先，这篇文章为关于 Covid-19 疫苗是否有资格获得专利的辩论提供了理由。市场失灵和研发投资不足的论点不适用于向 Covid 疫苗授予专利。接下来，文章简要回顾了疫苗接种与病毒突变之间关联的证据。有证据表明，放弃专利对于在全球范围内增加疫苗接种、遏制突变和降低更具传染性的新变种的风险至关重要。最后，